Sarepta to Present Long-Term Data on Gene Therapy, Exon-Skipping Treatments
Event summary
- Sarepta Therapeutics will present data at the Muscular Dystrophy Association (MDA) Clinical & Scientific Congress, March 8-11, 2026.
- Key presentations include a late-breaking oral presentation on delandistrogene moxeparvovec (gene therapy) with up to three years of follow-up data.
- Data will also be presented on golodirsen and casimersen (exon-skipping treatments) and a real-world analysis of survival in patients treated with Sarepta’s medicines.
- A pooled safety analysis of delandistrogene moxeparvovec clinical trials will cover up to 7.5 years of patient follow-up.
The big picture
Sarepta’s continued focus on long-term data generation underscores the increasing importance of demonstrating durable efficacy and safety in rare disease gene therapies. The company’s leadership position in this niche market, valued at approximately $3.5 billion, is predicated on maintaining a robust pipeline and generating compelling clinical evidence. The presentation at MDA represents a key opportunity to reinforce Sarepta’s position and address investor concerns regarding the long-term value proposition of its treatments.
What we're watching
- Clinical Validation
- The long-term safety and efficacy data on delandistrogene moxeparvovec will be critical in solidifying its commercial viability and justifying its premium pricing, especially given the scrutiny of gene therapy cost-effectiveness.
- Real-World Evidence
- The real-world survival analysis will provide a more nuanced view of treatment impact beyond controlled clinical trials, potentially influencing payer coverage decisions and patient access.
- Regulatory Risk
- The FDA’s assessment of the pooled safety data, particularly regarding adverse events within the first 60 days post-infusion, could impact future approval pathways for Sarepta’s gene therapy programs.
Related topics